Chemed Co.

Chemed shares closed at $552.05, marking a new 52-week high; market capitalization is about $7.15 billion and the stock is up 28.75% year-to-date. For the second quarter Chemed reported adjusted earnings of $6.06 per share on revenue of $673.25 million, beating analysts' expectations. Growth in hospice unit VITAS and steady results from Roto-Rooter drove the performance; the company also raised its outlook for the remainder of the year. » Plus sur de.investing.com

Activist investor Barington Capital is pressing Chemed for a comprehensive strategic review and is seeking a renewal of the board. Barington criticizes that Chemed’s two business units, Vitas Healthcare and Roto-Rooter, are not delivering maximum value and have underperformed their peer group and the market. The investor demands plans to boost profits, potential restructurings to strengthen Roto-Rooter, cost cuts including reductions in certain fringe benefits, and a revamp of the compensation program. Barington has already held talks with CEO Kevin McNamara and CFO Michael Witzeman and has nominated a candidate for the board. » Plus sur de.investing.com

Chemed’s stock reached a new 52-week high of $512.92 and is currently trading near that peak at $511.85. Over the past year the price rose 13.49%, and it is up 19.52% year-to-date. InvestingPro rates the stock as undervalued with a financial grade of "VERY GOOD." Chemed also beat Q1-2026 expectations (EPS $5.65 vs. $5.34, revenue $657.5m vs. $651.02m) and prompted an RBC price-target upgrade from $422 to $436; the advisory vote on executive compensation was rejected at the annual general meeting. » Plus sur de.investing.com

Chemed's stock traded at $492.42, marking a new 52-week high. The company beat expectations in Q1 2026 with EPS of $5.65 and revenue of $657.5 million, prompting RBC to raise its price target from $422 to $436. InvestingPro rates the stock as undervalued; Chemed has increased its dividend for 17 consecutive years and confirmed all eight board nominees, while the executive compensation plan was rejected. » Plus sur de.investing.com

Chemed’s stock marked a new 52-week high at $484.86 and trades just below the year high. The share is up 12.69% year-to-date and has gained 13.77% over six months. Chemed beat Q1 2026 analyst expectations with EPS of $5.65 and revenue of $657.5 million; RBC raised its price target to $436. At the annual meeting the board of directors was re-elected, but the advisory vote on executive compensation was rejected. » Plus sur de.investing.com